Cytokine Adsorption: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−72%

Mortality (2)−72%

RCTs (2)−72%

RCT mortality (2)−72%

Late (2)−72%

00.511.5+

← Cytokine
Adsorption
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Cytokine adsorption COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Supady (RCT)−250%3.50 · 1.44–8.48death14/174/17CYCOVECMO patients Stockmann (RCT)9%0.91 · 0.46–1.81death23 (n)26 (n)CytoRescVentilated patients

Late treatment−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.43

All studies−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.4300.511.52+

Rotate screen for more detailsIncrease width for more details

← Cytokine
Adsorption
reduces riskCytokine
Adsorption
increases risk →

c19early.org

October 2026

Cytokine adsorption COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Supady (RCT)−250%3.50 · 1.44–8.4814/174/17CYCOVECMO patients Stockmann (RCT)9%0.91 · 0.46–1.8123 (n)26 (n)CytoRescVentilated patients

Late treatment−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.43

All studies−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.4300.511.52+

Rotate screen for more detailsIncrease width for more details

← Cytokine Adsorption
reduces riskCytokine Adsorption
increases risk →

c19early.org

October 2026

Cytokine adsorption COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Supady (RCT)−250%3.50 · 1.44–8.48death14/174/17CYCOVECMO patients Stockmann (RCT)9%0.91 · 0.46–1.81death23 (n)26 (n)CytoRescVentilated patients

Late treatment−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.43

All studies−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.4300.511.52+

Rotate screen for more detailsIncrease width for more details

← Cytokine
Adsorption
reduces riskCytokine
Adsorption
increases risk →

c19early.org

October 2026

Cytokine adsorption COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Supady (RCT)−250%3.50 · 1.44–8.48death14/174/17CYCOVECMO patients Stockmann (RCT)9%0.91 · 0.46–1.81death23 (n)26 (n)CytoRescVentilated patients

Late treatment−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.43

All studies−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.4300.511.52+

Rotate screen for more detailsIncrease width for more details

← Cytokine
Adsorption
reduces riskCytokine
Adsorption
increases risk →

c19early.org

October 2026

Cytokine adsorption COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Supady (RCT)−250%3.50 · 1.44–8.4814/174/17CYCOVECMO patients Stockmann (RCT)9%0.91 · 0.46–1.8123 (n)26 (n)CytoRescVentilated patients

Late treatment−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.43

All studies−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.4300.511.52+

Rotate screen for more detailsIncrease width for more details

← Cytokine Adsorption
reduces riskCytokine Adsorption
increases risk →

c19early.org

October 2026

Cytokine adsorption COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Supady (RCT)−250%3.50 · 1.44–8.48death14/174/17CYCOVECMO patients Stockmann (RCT)9%0.91 · 0.46–1.81death23 (n)26 (n)CytoRescVentilated patients

Late treatment−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.43

All studies−72%1.72 · 0.46–6.4514/404/4372% higher risk

Tau² = 0.75, I² = 82.6%, p = 0.4300.511.52+

Rotate screen for more detailsIncrease width for more details

← Cytokine
Adsorption
reduces riskCytokine
Adsorption
increases risk →

c19early.org

October 2026

Cytokine adsorption COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Supady (RCT)−250%3.50 · 1.44–8.48death14/174/17CYCOVECMO patients Stockmann (RCT)9%0.91 · 0.46–1.81death23 (n)26 (n)CytoRescVentilated patients

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Cytokine
Adsorption
reduces riskCytokine
Adsorption
increases risk →